Advanced in ABO Incompatibility

Fritz Diekmann

Barcelona, CT, ES 
Advanced in ABO Incompatibility
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Fritz Diekmann practices in Barcelona, Spain. Mr. Diekmann is rated as an Advanced expert by MediFind in the treatment of ABO Incompatibility. His top areas of expertise are Chronic Kidney Disease, COVID-19, ABO Incompatibility, Kidney Transplant, and Pancreas Transplant.

His clinical research consists of co-authoring 195 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of ABO Incompatibility.

Gender
Male

Locations

Barcelona, CT, Spain
Other Locations
Madrid, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Enrollment Status: Terminated
Publish Date: July 23, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 3
Long-term Immunogenicity Study of Herpes Zoster Subunit Vaccine (GSK1437173A) and Immunogenicity and Safety Assessment of Revaccination With Two Additional Doses in Adults With Renal Transplant From Study ZOSTER-041
Long-term Immunogenicity Study of Herpes Zoster Subunit Vaccine (GSK1437173A) and Immunogenicity and Safety Assessment of Revaccination With Two Additional Doses in Adults With Renal Transplant From Study ZOSTER-041
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Biological
Study Drug: HZ/su vaccine (GSK1437173A)
Study Phase: Phase 3
A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference Cohorts
A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference Cohorts
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

195 Total Publications

Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation.
Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation.
Journal: Transplant international : official journal of the European Society for Organ Transplantation
Published: July 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Diekmann's expertise for a condition
ConditionClose
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile